Prostate cancer, BRCA-mutated
Revision as of 17:45, 12 February 2022 by Warner-admin (talk | contribs) (Text replacement - "|Phase II" to "|Phase 2")
Page editor | Section editor | ||
---|---|---|---|
Laura S. Graham, MD University of Washington Fred Hutchinson Cancer Research Center Seattle, WA ![]() |
Ali Raza Khaki, MD Stanford University Palo Alto, CA ![]() |
7 regimens on this page
8 variants on this page
|
Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.
Metastatic castration-resistant
Rucaparib monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
(TRITON2) | 2017-NR | Phase 2 (RT) |
Note: this study is the basis of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.
Targeted therapy
References
- TRITON2: NCT02952534